地舒单抗治疗绝经后骨质疏松症的疗效观察及对PINP、β-CTX的影响

Efficacy of denosumab on postmenopausal osteoporosis and its effect on PINP and β-CTX

目的观察地舒单抗治疗绝经后骨质疏松症的疗效及对血清PINP、β-CTX含量的影响。方法选取自2021年5月~2022年1月就诊的绝经后骨质疏松症患者80例,给予地舒单抗60 mg治疗,同时给予维D钙咀嚼片。比较治疗前及治疗6个月后患者腰椎骨密度、疼痛数字评定量表(NRS)评分、Oswestry功能障碍指数(ODI)评分变化情况及对血清Ⅰ型前胶原氨基端前肽(PINP)、Ⅰ型胶原羧基端肽β特殊序列(β-CTX)水平的影响。结果治疗6个月后,患者腰椎骨密度增加,差异有统计学意义(P<0.05);NRS评分以及ODI指数较治疗前均降低,差异有统计学意义(P<0.05);血清PINP、β-CTX水平较治疗前均下降,差异有统计学意义(P<0.05)。结论地舒单抗联合钙制剂的治疗可以明显改善绝经后骨质疏松患者的骨痛症状,提升骨密度,调节骨代谢生化等指标。

Objective To observe the efficacy of denosumab in the treatment of postmenopausal osteoporosis and the effects of PINP andβ-CTX content in serum.Methods Eighty postmenopausal patients with osteoporosis admitted to our hospital from May 2021 to January 2022 were selected.They were treated with denosumab 60 mg and vitamin D calcium chewable tablets.The changes of lumbar bone density,NRS pain score,ODI index score and their effects on serum PINP andβ-CTX levels were compared before treatment and 6 months after treatment.Results After 6 months treatment,lumbar bone density increased,and the difference was statistically significant(P<0.05).NRS score and ODI score were lower than before treatment,the differences were statistically significant(P<0.05).Serum PINP andβ-CTX levels were decreased compared with those before treatment,and the differences were statistically significant(P<0.05).Conclusion The treatment of denosumab combined with calcium preparation can significantly improve the clinical symptoms of bone pain in postmenopausal osteoporosis patients,increase bone density,regulate bone metabolism and biochemical indicators.